Product Images Dutasteride

This is a description of Dutasteride capsules, 0.5mg, which should be prescribed to men only. The text also includes warnings and safety information, such as not using the capsules if the safety seal is broken or missing and avoiding contact with the leaking capsule. Users of the drug should follow the usual dosage, which is 0.5mg once a day, and consume the capsules whole. The distributors of the product are GSMS, Incorporated, and the manufacturers are Ascent Pharmaceuticals, Inc.*

The image shows the change in the AUA-ST Score from baseline in randomized, double-blind, placebo-controlled trials pooled. The study was conducted over a period of 24 months, where patients were treated with either Placebo or Dutasteride. The AUA-ST score ranges from 0 to 35.*

This is a table or graph showing the percentage of subjects who had surgery for Benign Prostatic Hyperplasia over a 24-month period in randomized, double-blind, and placebo-controlled trials. The table or graph shows the time in months of treatment and the number of events cumulatively in both the placebo and dutasteride groups. The number at risk for both groups is also included.*

This is a graph titled "Figure 4" that shows the percent change in prostate volume from the baseline over the course of treatment in a randomized, double-blind, placebo-controlled trial. The x-axis depicts the months of treatment, and the y-axis shows the percentage of change in prostate volume. The graph compares two groups, one taking a placebo and the other taking Dutasteride. The data is broken down into multiple time intervals, and the number of participants in each group is also shown.*

Figure 6 shows the results of a study called the CombAT Trial, which was a randomized, double-blind, parallel-group trial that lasted 48 months. The graph displays the change in the International Prostate Symptom Score from baseline during this period. The x-axis shows the months of treatment, and the y-axis shows the score change. There are three groups included in the study: those treated with Dutasteride and tamsulosin (n=1575), those treated with Dutasteride 0.5 mg (n=1592), and those treated with Tamsulosin 0.4 mg (n=1582).*

This is a table showing the adverse reactions reported in more than 1% of subjects over a 24-month period and more frequently in the group receiving Dutasteride than the Placebo group in randomized, double-blind, placebo-controlled trials. The table includes the adverse reactions and the corresponding time of onset for both the Dutasteride and Placebo groups. The adverse reactions associated with Dutasteride include Impotence, decreased libido, ejaculation disorders, and breast disorders. The sexual adverse reactions may persist after the treatment discontinuation, and the role of dutasteride in this persistence is unknown. The breast disorders include breast tenderness and breast enlargement.*

The provided text is a table that contains adverse reaction rates for a combination of two medications, Dutasteride and Tamsulosin, compared to the response rates of two monotherapy options. The data is sorted by adverse reaction, such as ejaculation disorders, impotence, decreased libido, and breast disorders. The table also contains the time of onset for each set of reactions, which were reported over a 43-month period.*